Clinical Trials on Adenoma, Islet Cell in Japan

Total 933 results

Eli Lilly and Company

Completed

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

Japan
Eli Lilly and Company

Completed

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Multiple Myeloma

Japan
SymBio Pharmaceuticals

Terminated

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Multiple Myeloma

Japan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Cushings Disease

United States, Canada, Italy, India, Japan, Austria, Netherlands, Spain, Korea, Republic of, Germany, Thailand, France, Bulgaria, Turkey, Colombia, China, Argentina, Russian Federation, United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

Multiple Myeloma

Japan
Celgene

Completed

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Myelodysplastic Syndromes | Multiple Myeloma

Japan
Novartis Pharmaceuticals

Terminated

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Neoplasms, Haematologic

Japan
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AstraZeneca

Completed

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Part A and B: Advanced Solid Malignancies | Part C: Malignant Mesothelioma

Japan
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Lymphoma | Multiple Myeloma

Japan
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Non-Small-Cell Lung Carcinoma

Japan
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
Celgene

Completed

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Lymphoma, T-cell, Peripheral

Japan
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Institut de Recherches Internationales Servier
Kyowa Kirin Co., Ltd.; ADIR, a Servier Group company

Completed

A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Japan
AstraZeneca

Withdrawn

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Cancer | Non Small Cell Lung Cancer | Epithelial Ovarian Cancer

Japan
Duke University

Active, not recruiting

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

United States, Japan, Italy, Korea, Republic of, Czechia, Singapore
Eisai Co., Ltd.

Completed

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma

Japan
Celgene

Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
HUYABIO International, LLC.
Quintiles, Inc.

Completed

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma (PTCL)

Japan, Korea, Republic of
Pfizer

Active, not recruiting

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Japan
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Lymphoma, T-Cell

Japan
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
AbbVie

Completed

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
AstraZeneca

Completed

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

Japan
AstraZeneca

Active, not recruiting

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)

Carcinoma, Non-Small-Cell Lung | Small Cell Lung Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States, Taiwan, Korea, Republic of, Japan, Spain
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Cushing's Disease

Italy, Belgium, Japan, Germany, United Kingdom, Thailand, Spain, France, Netherlands, Turkey, Israel, China, United States, Canada, India, Argentina, Brazil, Peru, Poland, Russian Federation
University of Toyama

Unknown

Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus

Esophageal Cancer

Japan
University of the Ryukyus

Completed

Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease (DRC-04)

Coronary Artery Disease | Inflammation | Diabetes Mellitus, Type 2 | Diarrhea | Colchicine | White Blood Cell

Japan
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, United States, Israel
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
Hutchmed

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
Japan Multinational Trial Organization

Completed

Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Japan
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukemia

Japan
Eli Lilly and Company

Completed

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Squamous Non-small Cell Lung Cancer

Japan
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
Takeda

Completed

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Pfizer

Completed

Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Korea, Republic of, Japan, China
AstraZeneca

Completed

Nexium Capsules Clinical Experience Investigation

Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome

Japan
Novartis Pharmaceuticals

Terminated

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

Sickle Cell Disease

Bahrain, Kuwait, Qatar, Saudi Arabia
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Amgen

Recruiting

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Small-Cell Lung Cancer | Extensive-Stage Small-Cell Lung Cancer

United States, China, Japan, Switzerland, Turkey

3

Subscribe